New Data Demonstrates Potential Of ABRAXANE In Difficult-to-Treat Refractory Invasive Bladder Cancer

Links shared publicly online about this topic.

  • 1,122
    total visits

New Data Demonstrates Potential Of ABRAXANE In Difficult-to-Treat Refractory Invasive Bladder Cancer

medicalnewstoday.com —

Abraxis BioScience, Inc. (NASDAQ:ABII) announced today that findings from a phase 1 randomized trial demonstrated that the nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel

View full resource at medicalnewstoday.com

Tags: Cancer, Chemotherapy, Bladder Cancer, Urinary System, Urology

  • Share

Most Recently Shared on June 3, 2010 at 9:23 am By:

mnt_clinical MNT Clinical Trials

New Data Demonstrates Potential Of ABRAXANE In Difficult-to-Treat Refractory Invasive Bladder Cancer http://mnt.to/3DqN #clinicaltrials

2 years ago...

Reply

Retweet

Favorite

Also Shared By:

MNT Urology MNT Urology

Advertisement